Omega Therapeutics, Inc.

As of November 8, 2022, Omega Therapeutics, Inc. is considered overvalued and rated as risky due to significant financial challenges, including a P/E ratio of NA from losses, a price to book value of 0.15, an EV to EBITDA ratio of 0.02, a ROE of -633.21%, and a year-to-date return of -96.67%, which contrasts unfavorably with its peers.

As of March 31, 2025, the technical trend is mildly bearish with mixed signals, including a mildly bullish weekly MACD, bearish weekly RSI, and bearish daily moving averages, indicating a lack of strong bullish momentum.

Omega Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $3 million and a net loss of $16 million as of September 2024. The company has a market cap of $1.72 million and does not pay dividends.

As of Jun 18, Omega Therapeutics, Inc. has a market capitalization of 1.72 million, with net sales of 8.09 million and a net profit of -73.08 million over the last four quarters. Shareholder's funds total 58.02 million, and total assets are valued at 204.37 million.